

*In the Specification*

On page 1, please amend the first paragraph as set forth below:

This application is a divisional of United States Patent Application serial number 10/012,242, filed December 4, 2001; which claims the benefit of priority to United States Provisional Patent Applications serial numbers 60/251,209, filed December 4, 2000; and 60/275,600, filed March 13, 2001.

On page 7, please amend as set forth below the brief descriptions of Figures 16, 17, and 18:

**Figure 16** depicts peak retention times obtained from HPLC traces for various mixtures comprising a compound prepared according to the methods of the present invention.

**Figure 17** depicts peak retention times obtained from HPLC traces for various mixtures comprising a compound prepared according to the methods of the present invention.

**Figure 18** depicts peak retention times obtained from HPLC traces for various mixtures comprising a compound prepared according to the methods of the present invention.

On page 75, please amend as set forth below Examples 41, 42, and 43.

**Example 41**

**Achiral (reverse-phase) HPLC analysis of 15 (See Figure 16)**

Figure 16 depicts a series of HPLC analyses (at both 254 and 220 nm) of compound **15** (8.42 min) alone in the first two ~~plots~~ analyses, compound **15** co-injected with a mixture of compounds **15** and **16** in the 3<sup>rd</sup> and 4<sup>th</sup> ~~plots~~ analyses, and of a mixture of compounds **15** and **16** in the 5<sup>th</sup> and 6<sup>th</sup> ~~plots~~ analyses. The peak at 8.78 min. is an impurity.

**Example 42**

**Achiral (reverse-phase) HPLC analysis of 16 (See Figure 17)**

Figure 17 depicts a series of HPLC analyses (at both 254 and 220 nm) of compound **16** (8.16 min) alone in the first two ~~plots~~ analyses, compound **16** co-injected with a mixture of compounds **15** and **16** in the 3<sup>rd</sup> and 4<sup>th</sup> ~~plots~~ analyses, and of a mixture of compounds **15** and **16** in the 5<sup>th</sup> and 6<sup>th</sup> ~~plots~~ analyses.

**Example 43**

**Achiral (reverse-phase) HPLC analyses of 15 and 16 (See Figure 18)**

Figure 18 depicts a series of HPLC analyses (at both 254 and 220 nm) of compound **15** (8.42 min) alone in the first two ~~plots~~ analyses, compound **15** co-injected with compound **16** in the 3<sup>rd</sup> and 4<sup>th</sup> ~~plots~~ analyses, and compound **16** in the 5<sup>th</sup> and 6<sup>th</sup> ~~plots~~ analyses.